Increased NOS2 predicts poor survival in estrogen receptor–negative breast cancer patients
Sharon A. Glynn(Ollscoil na Gaillimhe – University of Galway), Stefan Ambs(University of Maryland, Baltimore), Robert Hudson(National Cancer Institute), David A. Wink(National Cancer Institute), Harris G. Yfantis(University of Maryland, Baltimore), Brenda J. Boersma(Center for Cancer Research), Tiffany H. Dorsey(Center for Cancer Research), Christopher Switzer(Center for Cancer Research), Ming Yi(Science Applications International Corporation (United States)), Robert M. Stephens(National Cancer Institute), Lisa A. Ridnour(National Institutes of Health), Dong Hoon Lee(Korea University), Damali N. Martin(National Institutes of Health)
Cited by 250
Related Papers
Genomic Profiling of MicroRNA and Messenger RNA Reveals Deregulated MicroRNA Expression in Prostate Cancer
|Cancer Research|2008|708
The multifaceted roles of nitric oxide in cancer
|Carcinogenesis|1998|682
“NONOates” (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms
|Methods in enzymology on CD-ROM/Methods in enzymology|1996|674
Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men
|Cancer Research|2008|522
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis
|Journal of Clinical Investigation|2013|469